Liver transplant induction trial of daclizumab to spare calcineurin inhibition.
Heffron
T G
TG
Department of Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA.
Smallwood
G A
GA
Pillen
T
T
Davis
L
L
Martinez
E
E
Romero
R
R
Stieber
A C
AC
D000328:Adult; D000367:Age Factors; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D019703:Calcineurin / Q000502:physiology*; D065095:Calcineurin Inhibitors; D002648:Child; D000077561:Daclizumab; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006526:Hepatitis C / Q000453:epidemiology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology* / Q000401:mortality; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D012008:Recurrence; D015996:Survival Rate; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D065095:Calcineurin Inhibitors; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab; D019703:Calcineurin